# Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

> **NCT02301364** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Lymphoma
- Primary Central Nervous System Lymphoma
- Recurrent/Refractory Secondary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Buparlisib (BKM120)

## Key facts

- **NCT ID:** NCT02301364
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-20
- **Primary completion:** 2016-10-11
- **Final completion:** 2016-10-11
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2017-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02301364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02301364, "Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02301364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*